Effect of prophylaxis on the clinical manifestations of AIDS-related opportunistic infections

被引:15
作者
Sepkowitz, KA [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
关键词
D O I
10.1086/513920
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Administration of targeted prophylaxis for AIDS-related opportunistic infections has contributed significantly to the recent decrease in mortality among patients with AIDS in the United States. Most reported prophylaxis trials have focused on determining (a) the percentage of cases prevented and (b) the effect of widespread antibiotic use on drug susceptibility. A third phenomenon that is seldom reported on is the attenuating effect of failed prophylaxis on the clinical presentation of opportunistic infections (OIs). With the increasingly widespread use of prophylaxis for OIs, more atypical "breakthrough" cases of opportunistic infections will be seen. Reports of clinical changes are reviewed below. Investigators should routinely report the clinical manifestations of breakthrough cases in all articles pertaining to prophylaxis for opportunistic infections in patients with AIDS.
引用
收藏
页码:806 / 810
页数:5
相关论文
共 28 条
  • [1] Skin involvement with pneumocystis despite dapsone prophylaxis: A rare cause of skin nodules in a patient with AIDS
    Bundow, DL
    Aboulafia, DM
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1997, 313 (03) : 182 - 186
  • [2] *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1
  • [3] *CDCP, 1996, HIV AIDS SURV REP
  • [4] *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P165
  • [5] CHILIADE P, 1992, 7 INT AIDS C 22 24 J
  • [6] Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
    Gulick, RM
    Mellors, JW
    Havlir, D
    Eron, JJ
    Gonzalez, C
    McMahon, D
    Richman, DD
    Valentine, FT
    Jonas, L
    Meibohm, A
    Emini, EA
    Chodakewitz, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) : 734 - 739
  • [7] A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
    Hammer, SM
    Squires, KE
    Hughes, MD
    Grimes, JM
    Demeter, LM
    Currier, JS
    Eron, JJ
    Feinberg, JE
    Balfour, HH
    Dayton, LR
    Chodakewitz, JA
    Fischl, MA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) : 725 - 733
  • [8] Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both
    Havlir, DV
    Dube, MP
    Sattler, FR
    Forthal, DN
    Kemper, CA
    Dunne, MW
    Parenti, DM
    Lavelle, JP
    White, AC
    Witt, MD
    Bozzette, SA
    McCutchan, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (06) : 392 - 398
  • [9] Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: Results of a randomized controlled trial
    Hawken, MP
    Meme, HK
    Elliott, LC
    Chakaya, JM
    Morris, JS
    Githui, WA
    Juma, ES
    Odhiambo, JA
    Thiongo, LN
    Kimari, JN
    Ngugi, EN
    Bwayo, JJ
    Gilks, CF
    Plummer, FA
    Porter, JDH
    Nunn, PP
    McAdam, PWJ
    [J]. AIDS, 1997, 11 (07) : 875 - 882
  • [10] CLINICAL MANIFESTATIONS OF AIDS IN THE ERA OF PNEUMOCYSTIS PROPHYLAXIS
    HOOVER, DR
    SAAH, AJ
    BACELLAR, H
    PHAIR, J
    DETELS, R
    ANDERSON, R
    KASLOW, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (26) : 1922 - 1926